

August 22, 1973

Barrett Scoville, M.D.
Acting Director
Div. Neuropharmacological Drug Products
Bureau of Drugs, FDA
Rockville, Maryland 20852


Re: IND 9691

Dear Dr. Scoville,

In response to your letter of July 2, I am enclosing a reply prepared by the laboratory scientists at N.V. Organon who have been responsible for the basic studies of the compound, GB-94 (Mianserin). I believe their reply is responsive, and ask that this be made a matter of record for this project.

Thank you for your cooperation.

Sincerely yours,



Max Fink, M.D.
Professor of Psychiatry

Enc.: Ltr HvR
8-14-73